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A b s t r a c t
Gastrointestinal stromal tumors (GISTs) are
characterized by overexpression and mutations of c-Kit.
Approximately 80% of c-Kit mutations occur in exon
11, being a response factor to imatinib (Gleevec)
therapy. Mutations of platelet-derived growth factor
receptor-α (PDGFRA) are observed in a subset of
GISTs lacking c-Kit mutations.
We aimed to assess whether c-Kit and PDGFRA
mutation analysis of GISTs obtained by endoscopic
ultrasound–guided fine-needle aspiration (EUS-FNA)
could be routinely performed. Mutation analysis of c-
Kit hotspot exons (9, 11, 13, and 17) and PDGFRA
hotspot exons (12 and 18) was performed in aspirates
of 33 GISTs and 18 non-GIST mesenchymal tumors.
Of the GIST cases, 19 (58%) of 33 contained a
mutation in exon 11, 1 (3%) in exon 9, and none in
exons 13 and 17. No activating c-Kit mutations were
identified in non-GIST cases. No PDGFRA mutation
was detected.
Mutation analysis is possible in these FNA cell
blocks and can assist in the diagnosis and therapeutic
decisions in GIST cases.
Gastrointestinal stromal tumors (GIST) are the most
common mesenchymal tumors of the gastrointestinal tract,
with an annual incidence of 10 to 20 cases per million.1 GISTs
are rarely found outside the gastrointestinal tract, being most
commonly found in the stomach (40%-70%), small intestine
(20%-50%), colon and rectum (5%-15%), and esophagus
(<2%).2 These tumors are thought to arise from interstitial
cells of Cajal owing to their similar positive immunoreactivi-
ty for CD34 and CD117 (c-Kit), and to their lack of
immunoreactivity for desmin and S-100 protein. Interstitial
cells of Cajal are spindle-shaped cells located throughout the
gastrointestinal tract. They are specialized cells of the enteric
nervous system forming a network in the myenteric plexus
layer, which primarily controls gastrointestinal tract motility.3
Before 1998, almost all GISTs were misdiagnosed as smooth
muscle tumors such as leiomyomas, leiomyosarcomas, or
leiomyoblastomas.4,5 In 1998, Hirota et al6 described the
expression of c-Kit protein as an incontestable feature of
GISTs, further separating them from other gastrointestinal
mesenchymal tumors. At present, GIST is considered to be a
specific category different from true smooth muscle tumors
and neurogenic tumors.7
c-Kit belongs to the class III receptor tyrosine kinases
(RTKs), together with platelet-derived growth factor receptor-
α (PDGFRA), colony-stimulating factor-1 receptor (CSF-1-R),
vascular endothelial growth factor receptors 1 and 2 (Flt-1 and
Flk-1, respectively), Flk-2, and Flt-4. The RTKs are character-
ized by the presence of an extracellular domain, a transmem-
brane domain, a juxtamembrane domain, and an intracellular
domain where the 2 kinase domains are lodged.8 Activation of
c-Kit occurs when by the binding of stem cell factor, the
receptor homodimerizes and experiences conformational
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transformations that lead to the activation of the kinase domains.
These, in turn, transphosphorylate the tyrosine residues of the
opposing homodimerized receptor, allowing its association with
substrates of various kinds.8 Like the majority of RTKs, c-Kit
has been attributed many physiologic functions such as cell sur-
vival, proliferation, differentiation, adhesion, and apoptosis by
signaling through the MAP kinase, PI3-kinase, and JAK/STAT
pathways.9 c-Kit signaling is essential for normal erythropoiesis,
lymphopoiesis, gametogenesis, and melanogenesis and for the
correct development and function of mast cells.10 A dysfunction-
al activation of this RTK, therefore, has been involved in diverse
neoplasias such as mastocytosis/mast cell leukemia,11 germ cell
tumors,12 small cell lung carcinoma,13 acute myeloid leukemia,14
neuroblastoma,15 melanoma,16 ovarian carcinoma,17 and breast
carcinoma,18 besides GISTs.2,3,7,8
Mutations of the c-Kit oncogene are the major genetic
alterations in GISTs. There is a broad spectrum of c-Kit muta-
tions in GISTs, ranging from 30% to 90%, and c-Kit status
can constitute a prognostic factor for survival.19 Most of the
mutations are located in the juxtamembrane domain (exon
11), followed by the extracellular domain (exon 9), and sel-
dom are in the kinase domains (exon 13 and 17). Recently,
Heinrich et al20 showed that about 35% of GISTs lacking c-
Kit mutations have intragenic activation mutations in
PDGFRA, the most common, located in exons 12, 14, and 18.
Mutations of c-Kit and PDGFRA seem to be mutually exclu-
sive oncogenic events in GISTs.20
Until recently, the prognosis of patients with GISTs was
poor owing to its frequent recurrence and resistance to
chemotherapy and radiotherapy regimens.21 The development
and current treatment with specific RTK inhibitors is chang-
ing this scenario. Imatinib mesylate (Gleevec) is a selective
inhibitor of RTKs; by competing with the adenosine triphos-
phate for its binding site, preventing further phosphorylation
of signaling molecules downstream of the receptor, it is
responsible for abnormal viability and proliferation signals in
these cells.22 Several studies have linked different responses to
the drug with c-Kit alterations. In particular, tumors harboring
exon 11 c-Kit mutations are more likely to respond to imatinib
therapy than those with exon 9 c-Kit mutations or no
detectable mutation.23 On the other hand, some mutations,
such as D816V, are linked to imatinib response.23 Currently,
imatinib is used for the treatment of patients with c-Kit
(CD117)-positive GIST with unresectable and/or metastatic
malignant tumor.24 Besides imatinib, another RTK inhibitor,
sunitinib (Sutent), has been recently approved for the treat-
ment of patients with GIST whose disease has progressed or
who are unable to tolerate treatment with imatinib.25
It is a fact that obtaining an accurate diagnosis is of utmost
importance for correct treatment; an earlier diagnosis is cru-
cial for prompt therapy. Endoscopic ultrasound–guided fine-
needle aspiration (EUS-FNA) biopsy has been increasingly
used for the assessment of diverse intra-abdominal and
intrathoracic tumors.26,27
EUS-FNA biopsy not only allows for a meticulous repre-
sentation of extramural and intramural structures of the gas-
trointestinal tract but also permits tissue sampling from masses
in these locations.28,29 In the present study, we aimed to perform
molecular analysis of c-Kit and PDGFRA genes in formalin-
fixed, paraffin-embedded cell blocks obtained by EUS-FNA
biopsy from GISTs and non-GISTs. The feasibility of such
analysis would lead to a more precise diagnosis and therapeutic
decision in routine management of patients with GISTs (partic-
ularly patients with recurrent or imatinib-resistant tumors).
Materials and Methods
Tissue Samples
Between January 2000 and December 2005, 85 patients
with intramural gastrointestinal mesenchymal tumors were
diagnosed by EUS-FNA biopsy at Hennepin County Medical
Center, Minneapolis, MN. These tumors were preclassified by
the pathology department as 48 GISTs, 5 schwannomas, 27
leiomyomas, and 5 nonspecified spindle cell tumors.
Original classification of the tumors was based on
immunocytochemical analysis for GIST (CD117+/CD34+),
schwannoma (S-100 protein+/CD117–), and leiomyoma
(actin+/desmin+/CD117–). Case selection for the study was
based on specimen availability for molecular and immunocy-
tochemical analysis. Cell blocks of the initial 85 cases were
obtained; however, molecular analysis and complete repeated
immunocytochemical analysis were possible in 49 cases, and
in 2 cases, it was possible to perform only molecular analysis.
Original and repeated immunocytochemical results were com-
pared. ❚Table 1❚ lists the 51 cases, which included 33 GISTs,
14 leiomyomas, and 4 schwannomas. The mean age of
patients was 62.5 years (range, 26-92 years). Of the patients,
20 (39%) were women and 31 (61%) were men.
Topographically, 12 tumors (24%) were located in the esoph-
agus, 35 (69%) were gastric, and 4 (8%) were located in the
small intestine. The mean tumor size documented by EUS was
33.9 mm (range, 11-80 mm). The clinicopathologic features
of the cases are summarized in Table 1.
c-Kit Immunocytochemical Studies
Immunocytochemical studies of the 51 cases were per-
formed in material obtained from cell blocks. The procedure
was performed according to streptavidin-biotin-peroxidase
complex principle, using rabbit polyclonal antihuman anti-
bodies raised against c-Kit (clone A 4502, dilution 1:50;
DAKO, Carpinteria, CA), as previously described.30 Briefly,
deparaffinized and rehydrated slides were subjected to 10
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minutes’ incubation in 3% hydrogen peroxide in methanol to
inhibit endogenous peroxidase. No antigen retrieval was
used. After incubation with the primary antibody at room
temperature for 2 hours, the secondary biotinylated goat anti–
polyvalent antibody was applied for 10 minutes, followed by
incubation with streptavidin-peroxidase complex. The
immune reaction was visualized with 3,3'-diaminobenzidine
(DAB) as the chromogen (Ultravision Detection System Anti-
polyvalent, HRP/DAB; Lab Vision, Fremont, CA). Appropriate
positive and negative control samples were included in each run:
a case of gastrointestinal stromal tumor with previously charac-
terized c-Kit overexpression was used as a positive control
sample. For negative control samples, primary antibodies were
omitted. All sections were counterstained with hematoxylin.
DNA Isolation
Selected areas that contained at least 85% of tumor tissue
were microdissected under microscopic view and collected
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❚Table 1❚
Clinical Data for 51 Patients
Case No./Sex/Age (y) Size by EUS (mm) Location CD117 c-Kit Mutations Final Diagnosis
1/F/67 Unknown Gastric + Exon 11: V555V, V560D, L576F GIST
2/M/77 27 Gastric + Exon 11: Y553N GIST
3/F/82 35 Gastric + Exon 11: V560D GIST
4/M/92 48 Gastric + Exon 11: 563del574, insGGGTCC GIST
5/F/70 20 Gastric + Exon 11: 557del558 GIST
6/M/69 63 Gastric + Exon 11: V560D GIST
7/M/72 55 Gastric + Wild type GIST
8/M/47 Unknown Gastric + Exon 11: V560D GIST
9/F/75 13 Gastric + Exon 11: V560D GIST
10/F/72 24 Intestine + Wild type GIST
11/F/82 35 Intestine + Wild type GIST
12/M/79 37 Esophagus + Exon 11: 579dup582, E583E, F584N GIST
13/F/86 36 Gastric + Wild type GIST
14/M/64 26 Gastric + Exon 11: W557C, 558del560 GIST
15/M/66 48 Gastric – Wild type GIST
16/F/48 56 Gastric – Wild type GIST
17/M/84 25 Gastric – Wild type GIST
18/M/68 10 Gastric – Wild type GIST
19/F/51 41 Gastric + Wild type GIST
20/F/51 47 Gastric + Exon 11: V559del GIST
21/F/36 30 Gastric + Wild type GIST
22/M/78 13 Gastric – Wild type GIST
23/M/76 23 Gastric NA Exon 11: N567S GIST
24/F/65 57 Gastric + Exon 11: W557C, 558del560 GIST
25/F/82 43 Gastric – Wild type GIST
26/M/69 13 Gastric – Wild type GIST
27/M/52 76 Intestine NA Exon 11: V559A GIST
28/M/49 80 Gastric + Exon 11: 554del556 GIST
29/M/89 18 Gastric + Exon 11: 554del556 GIST
30/M/54 15 Gastric + Exon 11: V560D GIST
31/M/64 40 Gastric + Exon 11: 555del559 GIST
32/F/44 28 Gastric + Exon 9: 502dup503 GIST
33/M/59 33 Gastric + Exon 11: 557del558 Suggestive of GIST
34/M/57 46 Esophagus – Exon 11: L590L Leiomyoma
35/M/74 11 Gastric – Wild type Leiomyoma
36/M/52 69 Esophagus – Wild type Leiomyoma
37/M/41 28 Esophagus – Wild type Schwannoma
38/M/48 74 Gastric – Exon 11: E561E Leiomyoma
39/M/79 25 Gastric – Wild type Leiomyoma
40/M/50 22 Esophagus – Wild type Leiomyoma
41/F/54 17 Esophagus – Wild type Leiomyoma
42/M/65 30 Gastric – Wild type Leiomyoma
43/M/26 45 Esophagus – Wild type Leiomyoma
44/F/72 18 Esophagus – Wild type Schwannoma
45/M/49 17 Esophagus – Wild type Leiomyoma
46/F/41 41 Esophagus – Wild type Leiomyoma
47/M/47 32 Esophagus – Wild type Leiomyoma
48/F/62 34 Esophagus – Wild type Leiomyoma
49/F/61 14 Gastric – Wild type Leiomyoma
50/F/36 13 Gastric – Wild type Schwannoma
51/M/52 33 Intestine – Wild type Schwannoma
EUS, endoscopic ultrasound; GIST, gastrointestinal stromal tumor; NA, not available; +, positive; –, negative.
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into a microfuge tube using a sterile needle (Neolus, 25 gauge,
0.5 mm, Terumo, Tokyo, Japan). The dissected tissue was
deparaffinized by a serial extraction with xylol and ethanol
(100%-70%-50%) and allowed to air dry. DNA was extracted
using the QIAamp DNA Micro Kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. DNA
samples were stored at –20°C for further analysis.
c-Kit Mutation Analysis
c-Kit mutation analysis was performed as previously
described.31 DNA was subjected to polymerase chain reaction
(PCR) amplifications of exons 9, 11, 13, and 17 of the c-Kit
gene. Briefly, the PCR reaction was carried out in a final vol-
ume of 25 µL under the following conditions: 1× Buffer
(Bioron, Ludwigshafen, Germany); 1.5 mmol/L of magne-
sium chloride (Bioron); 200 µmol/L of deoxyribonucleotide
triphosphates (dNTPs; Fermentas, Burlington, Canada); 0.5
µmol/L of primers (DNA Technology, Aarhus, Denmark; pre-
viously described by Corless et al3), and 1 U of Super Hot Taq
Polymerase (Bioron).
PCR amplification was followed by single-strand confor-
mation polymorphism (SSCP) analysis of exons 9, 13, and 17
of c-Kit in a 1× mutation detection enhancement gel
(Cambrex, North Brunswick, NJ), with 6% glycerol added in
the exon 13 analysis. Twenty microliters of the PCR product
were incubated at 95°C for 10 minutes with an equal volume
of formamide loading buffer (98% formamide, 10 mmol/L of
EDTA, and 1 mg/mL of bromophenol blue and xylene
cyanol). SSCP gels were run at 20°C for exons 9, 13, and 17.
Samples with an SSCP pattern different from the normal pat-
tern were directly sequenced. Direct sequencing of exons 9,
11, and 13 was done with the following internal primer set: 5'-
AGCCAGGGCTTTTGTTTTCT-3' (forward, exon 9); 5'-
CAGAGCCTAAACATCCCCTTA-3' (reverse, exon 9); 5'-
GTGCTCTAATGACTGAGACAATAAT-3' (forward, exon
11); 5'-ACCCAAAAAGGTGACATGGA-3' (reverse, exon
11); 5'-CATCAGTTTGCCAGTTGTGC-3' (forward, exon
13); and 5'-ACACGGCTTTACCTCCAATG-3' (reverse, exon
13). All cases were confirmed twice with new PCR amplifica-
tion, direct sequencing, and SSCP analysis.
PDGFRA Mutation Analysis
Tumors with a wild-type c-Kit gene were further
screened for hotspot PDGFRA mutations (exons 12 and 18)
as previously described.30 Briefly, the PCR reaction was car-
ried out in a final volume of 25 µL, under the following con-
ditions: 1× Buffer (Bioron); 1.5 mmol/L of magnesium chlo-
ride (Bioron); 200 µmol/L of dNTPs (Fermentas); 0.5 µmol/L
of primers (DNA Technology; previously described by Corless
et al3), and 1 U of Super Hot Taq Polymerase (Bioron). PCR
was followed by direct sequencing. Direct sequencing of
both exons was done with the following internal primer set:
5'-CCTAGTCGGTCAGAACGT-3' (forward, exon 18); 5'-
GACCAGTCCGAGTAGGAG-3' (reverse, exon 18); 5'-
CTCTGGTGCACTGGGACTTT-3' (forward, exon 12); and
5'-AAAGGGAGTCTTGGGAGGTT-3' (reverse, exon 12).
Direct sequencing results were confirmed with a new PCR
amplification and direct sequencing procedure.
Statistical Analysis
Clinical and molecular data were analyzed with StatView
for Windows, version 5.0. A P value less than .05 was consid-
ered significant.
Results
Immunocytochemical Results
All non-GIST cases were immunonegative for CD117 (c-
Kit). The tumor cells were immunoreactive for S-100 protein
or actin and desmin in all schwannoma and leiomyoma cases,
respectively (data not shown). In 2 cases (cases 23 and 27), the
immunostaining was not interpretable owing to technical arti-
facts (Table 1). Immunoreactivity for CD117 was detected in
a majority of the remaining 31 tumors preclassified as GISTs.
In 77% (24/31) of GIST tumors, CD117 positivity was strong-
ly present at the membrane and diffuse in the cytoplasm
❚Image 1❚. CD117 was negative in 7 (23%) of 31 tumors pre-
classified as GISTs. 
c-Kit Screening
PCR amplification and DNA sequencing revealed exon 11
mutation in 19 (58%) of 33 GISTs and exon 9 mutation in 1
GIST (3%). Among the GISTs with c-Kit mutations, sequence
analysis of exon 11 showed in-frame deletions of 3 to 33 base
pairs (9/19 tumors [47%]) alone (6 tumors [67%]) or associat-
ed with missense mutations or insertions (3 tumors [33%]),
single base substitutions (9 tumors [47%]), and an in-frame
insertion associated with point mutation (1 tumor [5%]). A
case-by-case listing of these mutations is shown in ❚Table 2❚
and ❚Table 3❚. The exon 9 sequence alteration consisted of Ala-
Tyr duplication between codons 502 and 503. No exon 13 or
exon 17 mutations were detected. Of 33 GISTs, 13 (39%) had
wild-type c-Kit. In non-GIST cases, all but 2 had no identifi-
able c-Kit sequence alteration ❚Image 2❚. In these 2 cases, a sin-
gle base substitution translated to a silent mutation in both
cases (leiomyomas), not changing the codified amino acid.
PDGFRA Mutation Screening
No PDGFRA activating mutations were detected in the c-
Kit wild-type–bearing tumors. Mutational analysis of exon 18
showed the presence of a base insertion in the intron preced-
ing exon 18, ie, IVS18-50insA. Mutation analysis of exon 12
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showed the presence of a homozygous substitution of an ade-
nine for a guanine (polymorphism R) in the third position of
the codon coding for proline 567. All cases analyzed showed
both polymorphisms.
Statistical Analysis
Tumor type was statistically correlated with patient age
(P = .022); the median age for patients with GISTs was 67.8
years; with leiomyoma, 55.8 years; and with schwannoma,
43.0 years. Statistical significance was maintained when com-
paring GISTs with other tumors (P = .013).
Tumor type was also statistically correlated with common
gastric topography (P < .0001), CD117 expression (P < .001),
and presence of a c-Kit mutation (P = .0105). All cases with
mutated c-Kit were preclassified as GIST tumors. For GIST
cases, expression of CD117 was correlated with presence or
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❚Image 1❚ A, A cell block obtained from fine-needle aspiration (FNA) biopsy of a gastrointestinal stromal tumor (GIST) showing
spindle-cell morphologic features (H&E, ×200). B, Strong positivity for CD117 in a cell block obtained from FNA biopsy of a GIST
(×100). Inset, Cytoplasmic and membrane reactivity and absence of nuclear staining (×400).
❚Table 2❚
Amino Acid Sequence of Exon 11 of Wild-Type and Mutated c Protein*
550 560 570 580
Wild type K P M Y E V Q W K V V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
Case No.
1 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q F P Y D H K W E F P R N R L
2 K P M N E V Q W K V V E E I N G N N Y V Y I D P T Q N P Y D H K W E F P R N R L
3 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
4 K P M Y E V Q W K V V E E _ _ _ _ _ _ _ _ _ _ _ _ Q L P Y D H K W E F P R N R L
5 K P M Y E V Q _ _ V V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
6 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
8 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
9 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
12 K P M Y E V Q W K V V E E I N G N N Y V Y I D P T Q L P Y D H K W D H K W E N P
14 K P M Y E V Q C _ _ _ E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
20 K P M Y E V Q W K _ V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
23 K P M Y E V Q W K V V E E I N G N S Y V Y I D P T Q L P Y D H K W E F P R N R L
24 K P M Y E V Q C _ _ _ E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
27 K P M Y E V Q W K A V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
28 K P M Y _ _ _ W K V V E E I N G N N Y V Y I D P T Q P P Y D H K W E F P R N R L
29 K P M Y _ _ _ W K V V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
30 K P M Y E V Q W K V D E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
31 K P M Y E _ _ _ _ _ V E E I N G N N Y V Y I D P T Q F P Y D H K W E F P R N R L
33 K P M Y E V Q _ _ V V E E I N G N N Y V Y I D P T Q L P Y D H K W E F P R N R L
* Underscore indicates deleted amino acid residues.
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absence of c-Kit mutations (P < .003). All immunonegative
GIST cases had wild-type c-Kit, and all cases with mutated c-
Kit expressed CD117.
No other statistical significance was obtained for any
other variables.
Discussion
GISTs comprise a broad clinical spectrum from benign,
incidentally detected intramural nodules to severe, locally
aggressive, or metastatic malignant tumors. Because they are
generally resistant to chemotherapy and radiotherapy, the pre-
ferred treatment modality for GIST is surgery. The intensive
cancer research during the last decade demonstrated the fun-
damental role of RTK, in particular kit in the pathogenesis of
GIST. c-Kit has become more than just a diagnostic marker; it
is actually of great value for therapeutic approaches given the
development of RTK inhibitors such as imatinib.32,33
In the present study, we have shown that 77% of GISTs
strongly and diffusely express c-Kit, irrespective of tumor
topography or patient age or sex. Although several studies
indicate that 95% to 100% of GIST cases express c-Kit, lower
expression levels have been reported in Australian (78%) and
Scandinavian studies (85%).34,35 Such differences in protein
expression levels are probably due to distinct methods and
population diversity. We identified c-Kit mutations in 61% of
GIST cases, in accordance with previously published ranges
(30%-90%).
Nearly 95% (19/20) of c-Kit–mutant tumors carried exon
11 mutations. In 84% of these cases (16/19), mutations were
clustered in the region between codons 550 and 561, known to
be the most frequently altered section of exon 11, with 31%
affecting codons 557 or 558. These 2 codons are reported to
be associated with the metastatic behavior of GISTs.36
Besides having detected a single case bearing a known dupli-
cation in exon 9 (502dup503), no mutations were found in
exon 13 or 17 (kinase domains). Interestingly, although
reported to be associated with an intestinal localization, the
GIST case bearing a c-Kit exon 9 mutation had a gastric loca-
tion. Indeed, 88% of our FNA-GIST series was topographical-
ly classified as gastric. No colonic GISTs were identified in
this study, and this is most likely because most EUSs were
done in the upper gastrointestinal tract.
Even though it is well accepted that approximately 20%
of c-Kit wild-type–bearing GISTs harbor PDGFRA muta-
tions, none was detected in the present series. More interest-
ing is that despite the reported association between
PDGFRA mutants and gastric location and despite the loca-
tion of more than 85% of c-Kit wild-type–bearing GISTs in
the stomach, no genetic alteration in PDGFRA exon 12 or 18
was detected. Although methodological reasons cannot be
ruled out, our experience has shown a frequency of 31% of
PDGFRA mutations in Portuguese c-Kit wild-type GISTs
(personal observation).
❚Table 3❚
Amino Acid Sequence of Exon 9 of Wild-Type and Mutated c-
Kit Protein
495 600 510
Wild type N D V G K T S A Y F N F A F K G N
Case 32 N D V G K T S A Y A Y F N F A F K
C    A C    A A C T T C C T T A G T A C A G T G N A A G G
A B
❚Image 2❚ Sequencing analysis of 2 gastrointestinal stromal tumor cases representing the DNA sequence of exon 11 of c-Kit.
Each nucleotide is represented by 1 color. A (Case 28), Arrow indicates substitution of a thymine by a cytosine (L576P). B (Case
33), Arrow indicates beginning of deleted DNA sequencing (557del558).
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Imatinib was initially designed to inhibit the bcr/abl fusion
kinase protein in chronic myeloid leukemia and was later discov-
ered to be effective against GISTs with c-Kit and PDGFRA
mutations. Response to imatinib therapy is dependent on the
presence of activating mutations in either class III RTK; howev-
er, some patients have tumors with imatinib-resistant mutations.
Specifically, mutations affecting the juxtamembrane domain
(exon 11; partial response in 83.5%) or the extracellular domain
(exon 9; partial response in 47.8%) are responsive to imatinib,
whereas mutations in the other 2 c-Kit hotspots are predominant-
ly resistant, ie, V654A and W670I (in kinase domain 1, exon 13)
and D816V and T823D (in kinase domain 2, exon 17).19,37,38
Regarding the PDGFRA mutation, the majority of alter-
ations affecting codon 842 in exon 18 (corresponding to exon
17 of c-Kit) are known to be imatinib-resistant.1,32 Even so,
approximately 40% of patients with GISTs lack activating
mutations in either RTK, and most are consequently not
responsive to imatinib.1,32 In early 2006, the US Food and
Drug Administration approved a new RTK inhibitor, sunitinib
(Sutent) for the treatment of patients with GIST whose disease
has progressed or who are unable to tolerate treatment with
imatinib.25 This recent RTK inhibitor has opened new doors to
other RTK-overexpressing tumors in view of the fact that pos-
itive therapy responses are obtained in the presence of the
wild-type RTK or the previously described imatinib-resistant
mutants.39 Progress has made it necessary to accurately define
the type of mutation present in these tumors.
EUS-FNA, a less costly, less risky, and less invasive strat-
egy than several other options, is an increasingly used proce-
dure for the diagnosis of gastrointestinal tumors. However, most
studies comprise small series and lack molecular analysis of the
key pathogenetic oncogenes (c-Kit and PDGFRA).26,28,40-42 In
the present study, we have shown that GISTs could be diag-
nosed preoperatively on EUS-FNA specimens. In addition to
immunocytochemical studies, molecular analysis can be done
on formalin-fixed, paraffin-embedded cell-block material
obtained from these aspirates, avoiding more invasive diagnos-
tic procedures to obtain a tissue diagnosis.
Nowadays, with 2 RTK inhibitors available, there is an
imperative need for redefining GIST diagnosis and including
molecular analysis of c-Kit and PDGFRA in the current diag-
nostic protocol so as to better and more quickly establish the
specific therapeutic approach to use for a particular patient.
We are unquestionably taking one step forward in the diagno-
sis of GIST by making the molecular analysis routinely feasi-
ble with a small sample.
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